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Summary
A major obstacle for successful axon regeneration in
the adult central nervous system (CNS) arises from
inhibitory molecules in CNS myelin, which signal
through a common receptor complex on neurons con-
sisting of the ligand-binding Nogo-66 receptor (NgR)
and two transmembrane coreceptors, p75 and LINGO-1.
However, p75 expression is only detectable in sub-
populations of mature neurons, raising the question
of how these inhibitory signals are transduced in neu-
rons lacking p75. In this study, we demonstrate that
TROY (also known as TAJ), a TNF receptor family mem-
ber selectively expressed in the adult nervous sys-
tem, can form a functional receptor complex with NgR
and LINGO-1 to mediate cellular responses to myelin
inhibitors. Also, both overexpressing a dominant-
negative TROY or presence of a soluble TROY protein
can efficiently block neuronal response to myelin in-
hibitors. Our results implicate TROY in mediating my-
elin inhibition, offering new insights into the molecu-
lar mechanisms of regeneration failure in the adult
nervous system.
Introduction
Damaged axons in the adult CNS are unable to sponta-
neously regenerate upon injury, in contrast to neurons
in the peripheral or embryonic nervous system. Such a
failure in regeneration is believed to arise from both a
decline in the intrinsic growth state of mature neurons,
as well as the presence of a nonpermissive environ-
ment in the injured adult CNS preventing axon growth
(reviewed in Schwab and Bartholdi, 1996; Horner and
Gage, 2000). In addition to the physical barrier formed
by the astrocytic scar tissue that develops at the lesion
site (Morgenstern et al., 2002), inhibition by both extra-
cellular matrix proteoglycans secreted by reactive glial
cells and inhibitory molecules associated with CNS my-
elin have been shown to restrict axon regeneration in
the adult nervous system (Schwab and Bartholdi,
1996). To date, three major inhibitory molecules in my-
elin have been characterized, including Nogo-A, my-
elin-associated glycoprotein (MAG), and oligodendro-
cyte myelin glycoprotein (OMgp), which collectively
account for the majority of the inhibitory activity in my-
elin (reviewed by Filbin, 2003; Yiu and He, 2003; He and
Koprivica, 2004). Though structurally distinct, all three*Correspondence: zhigang.he@childrens.harvard.edu
1These authors contribute equally to this work.myelin inhibitors signal through a common receptor
complex in neurons, which includes the ligand binding
Nogo-66 receptor (NgR), and two signal-transducing
binding partners, p75 and LINGO-1, to exert its effects
on the neuronal cytoskeleton and prevent axon growth
(Domeniconi et al., 2002; Liu et al., 2002; Wang et al.,
2002a, 2002b; Mi et al., 2004).
Although this receptor complex has been extensively
scrutinized as a convergence point for the inhibitory
signals of CNS myelin, it remains unclear whether other
coreceptors may also be involved. Interestingly, while
NgR and LINGO-1 are widely expressed in the adult
CNS (Figure 1; Wang et al., 2002c; Mi et al., 2004), p75
expression is much more restricted. Initially identified
as a low-affinity receptor for neurotrophins, p75 is
highly expressed in the developing nervous system
during periods of axon outgrowth and dendritic arbori-
zation, but decreases over the postnatal period and
adulthood (reviewed by Roux and Barker, 2002; Chao,
2003). In fact, only subpopulations of a few types of
mature neurons, such as subsets of dorsal root gan-
glion (DRG) neurons, have been shown to express p75
in adults (McMahon et al., 1994; Wright and Snider,
1995; Averill et al., 1995). Furthermore, though neurons
from p75 mutant mice are less inhibited by myelin com-
ponents in an in vitro neurite outgrowth assay, a signifi-
cant amount of residual inhibitory response remains
(Wang et al., 2002b). Consistent with this, studies with
p75 mutant mice have failed to show any significant
promotion of regeneration in an in vivo spinal cord in-
jury model (Song et al., 2004). Together, these results
suggest the possible presence of other functional ho-
mologs of p75 that allow neurons lacking this corecep-
tor to remain responsive to myelin inhibition.
p75 is a member of the TNF receptor (TNFR) family,
a class of type I transmembrane proteins bearing signif-
icant homology in their extracellular domains, which
contain one or more cysteine-rich domains (CRDs)
characteristic of this receptor superfamily (reviewed by
Locksley et al., 2001; Dempsey et al., 2003). However,
their cytoplasmic tails are highly divergent, with a broad
range of affinities for intracellular adaptors allowing for
different signaling specificities. While many TNFR fam-
ily members have been well characterized in the con-
text of injury and inflammation (Locksley et al., 2001;
Dempsey et al., 2003), recent studies are just beginning
to unveil their role in neuronal functions (Neumann et
al., 2002; Desbarats et al., 2003; Demjen et al., 2004).
In this study, we provide evidence for the involvement
of TROY (also known as TAJ), a newly identified mem-
ber of the TNF receptor family expressed in the adult
nervous system (Kojima et al., 2000), as a functional
homolog of p75 in mediating myelin inhibition. Like p75,
TROY can form a receptor complex with NgR and
LINGO-1 and mediate the outgrowth inhibition and sig-
naling pathways triggered by myelin inhibitors. More-
over, blocking the interaction of TROY with NgR by
different dominant-negative approaches efficiently abol-
ished neuronal responses to myelin inhibitors. These re-
sults implicate an important role for TROY in mediating
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346Figure 1. Expression of TROY, p75, NgR, and
LINGO-1 mRNA in the Adult CNS
(A–L) In situ hybridization with antisense
probes demonstrating the expression pattern
of TROY (A, E, I, and M), p75 (B, F, J, and N),
NgR (C, G, K, and O), and LINGO-1 (D, H,
L, and P) in the adult mouse CNS, including
cerebral cortex (A–D), cerebellum (E–H), dor-
sal root ganglia (I–L), and retina (M–P). p75
expression is limited to a subpopulation of
DRG cell bodies (arrowhead), but undetect-
able in other DRG cell bodies (arrow), corti-
cal neurons, cerebellar granule neurons, and
most RGCs. In contrast, TROY, NgR, and
LINGO-1 are expressed in most populations
of cells in these CNS tissues. GCL, ganglion
cell layer; IPL, inner plexiform layer; INL, in-
ner nuclear layer; OPL, outer plexiform layer;
ONL, outer nuclear layer. Scale bar, 150 M
(cortex, cerebellum, and DRG); 50 M (retina).
(Q–S) Immunocytochemistry with anti-TROY
antibodies demonstrating TROY expression
on cell bodies and neurites of cultured DRG
neurons. Neurons were costained with anti-
TROY and anti-β-tubulin antibodies. Scale
bar, 50 M.the inhibitory effects of myelin components on axon re- e
bgeneration.
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Results o
p
Both p75-Positive and p75-Negative Neurons a
Are Inhibited by Myelin Inhibitors l
The fact that p75 is not expressed in all mature neurons r
raises the question of why neurons lacking p75 expres- r
sion also fail to regenerate after axonal injury. One pos- i
sibility is that these neurons are inhibited in an NgR- o
independent manner. Alternatively, other functional b
equivalents of p75 may allow these neurons to remain t
responsive to myelin inhibitors. To distinguish these
npossibilities, we employed DRG neurons from adult
rats. Consistent with previous reports (McMahon et al., c
s1994; Wright and Snider, 1995), we found that only
60%–70% of DRG neurons expressed detectable levels 2
tof p75 (p75+) and that this subpopulation was mostly
distinct from those positively stained by Isolectin B4 m
s(IB4+), a marker for cell surface glycoconjugates on
neurons lacking p75 (Averill et al., 1995; Molliver et al., p
t1997). When cultured on immobilized inhibitory sub-
strates such as the extracellular domain of Nogo-A i
w(Nogo-66) or OMgp, most DRG neurons exhibited re-
duced neurite outgrowth regardless of p75 expression t
((see Figure S1A in the supplemental material available
with this article online). This neurite outgrowth inhibi- n
mtion is mediated by NgR receptor complexes, as over-xpression of a truncated NgR that retains the ligand
inding domain but not the coreceptor binding domain
Wang et al., 2002b) resulted in enhanced neurite out-
rowth on these inhibitory substrates in more than 90%
f the DRG neurons including both p75−/IB4+ cells and
75+/IB4− cells (Figure S1B). Similarly, overexpressing
truncated p75 lacking its intracellular domain also al-
owed significant neurite outgrowth in most DRG neu-
ons, including the p75−/IB4+ cells (Figure S1B). These
esults suggest that the response to myelin inhibitors
n neurons lacking p75 expression may be mediated by
ther potential p75 functional homologs that can also
e blocked by the truncated p75 in a dominant-nega-
ive manner.
In previous studies, although we found that DRG
eurons from p75 knockout mice were able to over-
ome the inhibitory effects of immobilized myelin sub-
trates as compared to wild-type neurons (Wang et al.,
002b), average neurite lengths were still shorter than
hose on PDL, indicating some residual response to
yelin inhibition. Yet, when the response of different
ubpopulations of DRG neurons (IB4+ and IB4−) from
75−/− mice were quantified separately, we found that
he majority of the cells that could overcome myelin
nhibition were IB4−, while most of the IB4+ neurons,
hich would represent the p75− population from wild-
ype animals, remained inhibited by myelin inhibitors
Figure S1C). Even within the IB4− population of DRG
eurons from p75−/− mice, average neurite lengths on
yelin substrates were still less than those on PDL
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some residual response to myelin inhibitors. Together,
these results provide further support for the potential
existence of other functional homologs of p75.
Expression of TROY in Adult CNS
In addition to p75, several other known members of the
TNFR family, including TROY (Kojima et al., 2000), CD40
(Tan et al., 2002), DR6 (Pan et al., 1998), and TNFR1A
(Yan et al., 2003), have been reported to be expressed
in the mature nervous system. To examine the possi-
bility of these molecules as potential p75 functional ho-
mologs, we first examined their expression patterns in
the adult CNS by in situ hybridization. We found that
several TNFR family members, including TROY (Figures
1A, 1E, 1I, and 1M), CD40, and DR6 (data not shown)
are highly expressed in most parts of the adult CNS,
including the cerebral cortex and cerebellum, as well
as most DRG and retinal ganglion neurons (RGCs). This
was in sharp contrast to the expression of p75, which
was limited to subpopulations of DRG neurons (Figure
1J) and undetectable in cerebral cortex, cerebellum,
and most RGCs (Figures 1B, 1F, and 1N). Consistent
with previous studies (Wang et al., 2002c; Mi et al., 2004),
both NgR (Figures 1C, 1G, 1K, and 1O) and LINGO-1
(Figures 1D, 1H, 1L, and 1P) are broadly expressed
across most of these CNS regions. Immunostaining of
DRG neurons in culture also showed colocalization of
signals from both anti-TROY and anti-β-tubulin anti-
bodies, demonstrating the expression of TROY in both
cell bodies and neurites of these neurons (Figures 1Q–
1S). Together, these results are consistent with the no-
tion that TROY can act as a coreceptor of NgR.
TROY Can Bind NgR to Form a Receptor Complex
To determine whether TNFR members expressed in the
CNS can substitute for the role of p75 as an NgR core-
ceptor, we first determined whether they could form a
receptor complex with NgR and LINGO-1. Using a cell
surface binding assay, we found that, like p75, an alka-
line phosphatase (AP) fusion protein containing the ex-
tracellular domain of TROY (AP-TROY) can bind to
NgR-expressing COS-7 cells (Figures 2A and 2B) with
an apparent kD of w10 nM for AP-TROY and w80 nM
for AP-p75. This is further supported by the fact that
neither AP-p75 nor AP-TROY can bind to a truncated
form of NgR (DN-NgR), which retains its ligand binding
domain but lacks the unique carboxy-terminal region
required for coreceptor binding (Figure 2A), suggesting
that p75 and TROY may bind to a similar region of NgR.
In contrast, neither CD40-AP nor DR6-AP showed any
detectable binding in the nanomolar range (Figure 2C).
When transfected into 293T cells, TROY can be coimmu-
noprecipitated with NgR and LINGO-1 (Figure 2D), dem-
onstrating that TROY, like p75, is capable of forming re-
ceptor complexes with NgR and LINGO-1.
Like p75, TROY and NgR/LINGO-1 Can Confer RhoA
Activation in COS-7 Cells
To further examine whether TROY can form a functional
receptor complex with NgR and LINGO-1, we examined
whether coexpression of NgR, p75, and LINGO-1 canallow nonneuronal cells to respond to myelin inhibitors
by activating RhoA, a required step in the signaling
pathways for myelin inhibition (Lehmann et al., 1999;
Niederost et al., 2002). Consistent with previous obser-
vations (Mi et al., 2004), we found that soluble myelin
inhibitors can activate RhoA in COS-7 cells cotrans-
fected with NgR, p75, and LINGO-1 (Figure 3B). More
importantly, we found that TROY can also substitute for
p75 in reconstituting this functional receptor complex
with NgR and LINGO-1 in responding to all three myelin
inhibitors (Figures 3A–3D). As expected, all three com-
ponents (NgR, LINGO-1, and p75 or TROY) were re-
quired to confer this Rho activation (Figure 3A). These
results further support the role of TROY as a functional
homolog of p75 in transducing the inhibitory signal of
myelin inhibitors.
Blocking TROY Activity Attenuates Neuronal
Response to Myelin Inhibitors
If TROY can function as a p75-like NgR coreceptor, one
prediction will be that a truncated TROY lacking its in-
tracellular domain, once overexpressed, will compete
for binding of endogenous coreceptors like p75 and
TROY to NgR, restricting neuronal response to myelin
inhibitors in a dominant-negative manner. To test this,
we generated recombinant herpes simplex viruses
(HSVs) expressing either full-length (FL-TROY) or domi-
nant-negative TROY (DN-TROY). DRG neurons infected
with these viruses do not show significant changes in
cell survival as indicated by Hoechst 33258 staining
and neurite outgrowth on the control PDL substrate
(data not shown). However, when expressed in cultured
DRG neurons, the truncated, but not full-length, TROY
dramatically enhanced neurite outgrowth of DRG neu-
rons on immobilized Nogo-66 (Figure 4A) and other my-
elin inhibitors (data not shown), including both the IB4+
and IB4− populations.
As our results suggested that DRG neurons from
p75−/− mice still retained some responsiveness to my-
elin inhibitors, we next examined whether such residual
activity could be blocked by overexpression of DN-
TROY. As shown in Figure 4B, DN-TROY resulted in fur-
ther recovery from the inhibitory effects of Nogo-66 in
both IB4+ and IB4− DRG neurons. However, the inhibi-
tion was not totally abolished, presumably because ex-
pression levels of the protein were not high enough to
completely displace the activity of endogenous TROY
and other potential coreceptors. Interestingly, expres-
sion of FL-TROY resulted in an enhanced inhibitory
response of IB4− neurons to Nogo-66 compared to
YFP-infected controls (Figure 4B). As these IB4− neu-
rons express p75 in wild-type animals, these results
suggest the possibility that overexpression of TROY
could rescue the neuronal response to myelin inhibitors
in p75−/− mice.
Based on these results, we further anticipated that
a TROY-Fc fusion protein containing the extracellular
domain of TROY, when supplied exogenously, would in-
terfere with receptor complex formation and disrupt the
response of cultured neurons to myelin inhibitors. As
shown in Figure 4C, inhibition of neurite outgrowth from
DRG neurons by Nogo-66 can be neutralized by the
Neuron
348Figure 2. TROY Binds NgR with Similar Affin-
ity as p75
(A) Visualization of cell surface binding of AP,
AP-p75, AP-TROY, and AP-Nogo-66 fusion
proteins to adherent COS-7 cells expressing
full-length or truncated NgR. While AP-
Nogo-66 can bind both the full-length and
truncated forms of NgR, AP-p75 and AP-
TROY selectively binds full-length NgR. Scale
bar, 50 M.
(B) Concentration-dependent cell surface
binding of AP, AP-p75, and AP-TROY fusion
proteins to adherent COS-7 cells expressing
full-length NgR. In comparison to AP, both
AP-TROY and AP-p75 bind to NgR in a con-
centration-dependent manner, with an ap-
parent kD of w10 ± 2 nM for AP-TROY and
w80 ± 15 nM for AP-p75.
(C) Quantification of cell surface binding of
alkaline phosphatase (AP) alone and AP-
p75, AP-TROY, AP-CD40, and AP-DR6 fu-
sion proteins (200 nM) to adherent COS-7
cells expressing full-length NgR. While AP-
p75 and AP-TROY can bind to NgR, AP-
CD40 and AP-DR6 show no significant bind-
ing as compared to AP controls. Statistical
analysis was done by Student’s t test (p <
0.005).
(D) NgR, TROY, and LINGO-1 form recep-
tor complexes. Coimmunoprecipitaton of
LINGO-1, p75, and NgR1 by anti-FLAG anti-
body from COS-7 cells coexpressing combi-
nations of NgR, HA-LINGO-1, or FLAG-
TROY. Expression of individual proteins was
detected by Western blotting analysis with
specific antibodies as indicated.addition of excess recombinant TROY-Fc, but not con- s
ltrol IgG, in the immobilized substrate. Similar results
were also obtained from experiments using other my-
melin inhibitors or solubilized myelin as substrates (data
not shown). These results further substantiated the in- a
tvolvement of TROY in mediating the inhibitory activity
of myelin inhibitors. h
u
tDiscussion
p
aUntil now, available evidence has suggested that the
tmajority of the inhibitory activity associated with CNS
wmyelin signal via a common receptor complex con-
csisting of NgR, LINGO-1, and p75. Yet, in contrast to
iNgR and LINGO-1, p75 is only expressed in limited
dpopulations of mature neurons in the adult CNS, even
cafter injury (Roux and Barker, 2002; Chao, 2003). In the
scurrent study, we have demonstrated that TROY, an-
gother TNF receptor family member broadly expressed
rin the adult CNS, can substitute for p75 as a coreceptor
dof NgR and LINGO-1 and mediate the inhibitory effects
oof myelin inhibitors. Like p75, TROY binds NgR with
tsimilar affinity, and together with LINGO-1 can reconsti-
gtute the activation of RhoA, a required step in the sig-
Tnaling pathways of myelin inhibition. Additionally, both
doverexpression of a truncated form of TROY lacking its
tintracellular domain and addition of a TROY-Fc fusion
eprotein can block neuronal response to myelin inhibi-
tors in a dominant-negative manner. Together, these re-ults suggest that TROY may act as a functional homo-
og of p75.
In addition to p75 and TROY, several other TNFR
embers have also been shown to be expressed in the
dult CNS. Our studies, however, failed to demonstrate
he ability of these TNFR members to bind NgR with
igh affinity, suggesting that p75 and TROY may be
nique among their relatives in mediating myelin inhibi-
ion. Nevertheless, these in vitro binding results do not
reclude the possibility that other TNFR members may
lso act as NgR coreceptors under physiological condi-
ions. Interestingly, although TNFR members had been
ell characterized in the context of inflammation and
ell survival, recent studies are now implicating their
nvolvement in axonal growth as well, although the un-
erlying mechanisms remain unclear. For example,
ross-linking Fas (also known as CD95) on cultured
ensory neurons has been shown to induce neurite out-
rowth (Desbarats et al., 2003). Consistently, functional
ecovery after sciatic nerve injury is delayed in Fas-
eficient mice and accelerated by local administration
f antibodies against Fas (Desbarats et al., 2003). On
he other hand, TNF seems to inhibit the neurite out-
rowth of cultured hippocampal neurons through the
NF receptor, as suggested by studies in TNF receptor-
eficient mice (Neumann et al., 2002). It will be impor-
ant in the future to determine whether these phenom-
na are mediated by the NgR receptor complex as well.
In light of the structural basis for the ability of NgR to
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349Figure 3. NgR, TROY, and LINGO-1 Expression Confers RhoA Acti-
vation by Myelin Inhibitors in COS-7 Cells
(A–C) RhoA activation as detected by GST-RBD pull-down assays
in COS-7 cells transfected with plasmids expressing NgR, NgR/
TROY, NgR/TROY/LINGO-1 (A), and NgR/TROY/LINGO-1 or NgR/p75/
LINGO-1 (B) after treatment with OMgp (100 nM), or NgR/TROY/
LINGO-1 after treatment with OMgp, Nogo-66, MAG (all at 100 nM)
(C) for 10 min. Expression of individual proteins was shown by
Western blot analysis with specific antibodies.
(D) Quantification of RhoA activation in cells expressing either NgR/
p75/LINGO-1 or NgR/TROY/LINGO-1 after treatment with OMgp.
Results from densitometric analysis are expressed as “fold activa-
tion” of basal activity (means ± SEM) and were obtained from three
independent experiments. Statistical analysis was done by Stu-
dent’s t test (p < 0.01) comparing RhoA activity of cells treated and
not treated with OMgp. NgR/TROY/LINGO-1-expressing cells do
not show a significant difference in RhoA activation when com-
pared to NgR/p75/LINGO-1-expressing cells.Figure 4. Blocking TROY Activity Attenuates Neuronal Response to
Myelin Inhibitors
(A) A truncated TROY lacking its intracellular domain attenuates
the neurite outgrowth inhibition by immobilized Nogo-66 in both
IB4+ and IB4− DRG neurons. Average neurite lengths (means ±
SEM) of rat DRGs infected with HSVs expressing either full-length
(FL-TROY) or dominant-negative TROY (DN-TROY) and cultured on
PDL or Nogo-66 were quantified. Statistical analysis was done by
one-way ANOVA (p < 0.0001). All groups grown on Nogo-66 are
significantly different from those grown on PDL. For both IB4+ and
IB4− neurons cultured on Nogo-66, those infected with DN-TROY
viruses are significantly different from those infected with FL-TROY.
(B) Dominant-negative TROY blocks the residual inhibitory re-
sponse of DRG neurons from p75−/− mice to Nogo-66. Average
neurite lengths (means ± SEM) of mouse DRGs infected with HSVs
expressing YFP (control), full-length TROY (FL-TROY), or dominant-
negative TROY (DN-TROY) on PDL or Nogo-66 were quantified.
Statistical analysis was done by one-way ANOVA (p < 0.0001). On
Nogo-66, both IB4+ and IB4− neurons expressing DN-TROY show
significant differences from those expressing YFP (Control) and FL-
TROY, and IB4− neurons expressing FL-TROY show a significant
difference from IB4- cells expressing YFP.
(C) TROY-Fc blocks the neurite outgrowth inhibition by immobilized
Nogo-66 in both IB4+ and IB4− DRG neurons. Average neurite
lengths (means ± SEM) of rat DRGs on PDL or Nogo-66 in the ab-
sence or presence of excess amounts of TROY-Fc were quantified.
Statistical analysis was done by one-way ANOVA (p < 0.0001). For
groups cultured on Nogo-66, those with the addition of TROY-Fc
are significantly different from groups cultured with the addition of
control IgG.interact with multiple binding partners (He et al., 2003;
Barton et al., 2003), it is not surprising that it can also
interact with more than one coreceptor. Yet, it remains
unclear whether these molecules provide functional re-
dundancy or whether they permit distinct signaling
properties in different cells. Recent studies suggest
that p75 is a component of three distinct receptor plat-
forms (with Trk receptors, NgR/LINGO-1, and sortilin)
that bind different ligands (neurotrophins, myelin inhibi-
tors, and proNGF) and, under different conditions, facil-
itate cell survival, growth inhibition, or cell death,
respectively (reviewed by Barker, 2004). Analogously,
TNF receptor family members may also be present in
different complexes to mediate various functions. While
the function of TROY remains to be clarified, determin-
ing the portion of p75, TROY, and perhaps other TNFreceptors present in NgR receptor complexes will help
shed some light on how myelin inhibition may be regu-
lated at the receptor level.
The implication that more than one TNF receptor
member may be involved in myelin inhibition adds a
new level of complexity to designing therapeutic strate-
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350sgies for treating CNS injury. Following injury, microglia
Mand astrocytes at the lesion site can secrete TNF and
cvarious other cytokines to induce an inflammatory re-
a
sponse (Tchelingerian et al., 1993; Renno et al., 1995). d
At the same time, TNF receptor family members are 4
texpressed not only in neurons but also in glial cells like
loligodendrocytes (Arnett et al., 2001; Matysiak et al.,
12002). It remains unclear whether these inflammatory
dresponses are harmful or beneficial for axon regenera-
v
tion or functional recovery. On the one hand, macro- p
phage activation and other inflammatory responses C
lhave been implicated as a potential approach to acti-
vate the intrinsic regenerative ability of injured neurons
A(Yin et al., 2003; Fischer et al., 2004; Ma et al., 2004).
THowever, these effects often result in the death of in-
(
jured neurons and supporting glial cells. For example, c
a recent study demonstrated that neutralization of Fas f
ligand, but not TNF, could significantly decrease apo- i
Nptotic cell death and promote axon regeneration and
2functional recovery after spinal cord injury (Demjen et
cal., 2004). Further characterization of the underlying
e
mechanisms of these findings and their relation to my- b
elin inhibition may provide important insights into 3
designing therapeutic strategies to block myelin inhibi- q
ption and cell death in the context of CNS injury.
n
nExperimental Procedures
o
Generation of Recombinant Proteins and Viruses
IAP, Fc, AP-Nogo-66, and AP-OMgp were prepared as described
Mpreviously (Wang et al., 2002a, 2002b). For generation of recombi-
Dnant HSV, cDNA sequences of full-length and truncated (aa 30–193)
Nmouse TROY were first subcloned into pFLAG-CMV-1 (Sigma) to
gexpress FLAG-TROY fusion proteins and were ligated to the
upHSVprPUC vector (kindly provided by R. Neve) for HSV pro-
(duction. Similarly, cDNA sequences of full-length and truncated (a.a
F30–271) rat p75 were subcloned into pSECTAG-A (Invitrogen) to
4express myc-p75 fusion proteins and were ligated to the
fpHSVprPUC vector. These plasmids were then transfected into 2-2
tcells and then superinfected with herpes simplex 5dl1.2 helper
gvirus 1 day later (Neve et al., 1997).
wFor generation of lentiviruses, cDNA sequences of full-length and
truncated mouse TROY were subcloned into pSECTAG-A (Invitro-
gen) to express myc-tagged fusion proteins and then were ligated
Sto the HRST-IRESeGFP vector (kindly provided by R. Mulligan).
Lentiviral vectors for full-length and truncated p75, as well as full-
Slength and truncated NgR, have been described previously (Wang
let al., 2002b). Lentiviral constructs were cotransfected with vesicu-
lar stomatitis virus glycoprotein (VSV-G) and HIV-1 packaging vec-
tor 8.9 into 293T cells to generate recombinant lentiviruses (Wang
Aet al., 2002b). For both lentiviruses and HSVs, pilot tests were per-
formed to ensure thatw90% of the cultured neurons were infected
Wprior to performing experiments.
g
aRho Activation Assay
bFor Rho activation assays, transfected COS-7 cells were cultured
Movernight and subsequently stimulated with individual inhibitors or
their respective controls. GTP-Rho was precipitated using beads
with the GST-Rho binding domain (RBD) of Rhotekin and was de- R
tected with an anti-Rho antibody (Santa Cruz) following the manu- R
facturer’s instructions (Upstate Biotechnology). The intensity of the A
bands were quantified by densitometric analysis using Scion Image P
software (Scion, Frederick, MD), and amounts of GTP-bound RhoA
were normalized to the total amounts of RhoA in cell lysates. R
ANeurite Outgrowth Assay
Neurite outgrowth assays were performed as described previously a
d(Wang et al., 2002a, 2002b). Briefly, 4-week-old mouse or rat DRGs
were dissected, dissociated, and plated onto immobilized sub- 1trates (PDL, AP-Nogo-66 [100 ng/cm2], AP-OMgp [100 ng/cm2],
AG-Fc [100 ng/cm2], and myelin [50 ng/cm2]). For viral infections,
ells were trypsinized 3 days (for lentiviruses) or 1 day (for HSVs)
fter infection and were replated onto the immobilized substrates
escribed above. Cells were cultured for 24 hr before fixation with
% paraformaldehyde and staining with a neuronal-specific anti-β-
ubulin III antibody (Tuj-1, Covance). The average lengths of the
ongest neurite in individual neurons were measured from at least
50 neurons per condition, from duplicate wells and from three in-
ependent experiments, and were quantified as described pre-
iously (Wang et al., 2002a, 2002b). Immunohistochemistry was
erformed using antibodies against p75 (Chemicon), TROY (Santa
ruz Biotechnology), or Alexa Fluor 488-conjugated IB4 (Molecu-
ar Probes).
P Binding Assay and Immunoprecipitation
he cDNA sequence for the extracellular domain of mouse TROY
aa 30–169), CD40 (aa 26–193), and DR6 (aa 42–351) were sub-
loned into the expression vector APTag-5 (a gift of Dr. J. Flanagan)
or expression of AP-TROY, AP-CD40, and AP-DR6 fusion proteins
n 293T cells. The construction and generation of recombinant AP-
ogo-66 and AP-p75 were described previously (Wang et al.,
002b). Cell surface binding was performed by incubating the indi-
ated concentrations of each AP fusion protein with COS-7 cells
xpressing full-length or truncated human NgR. For visualization of
ound AP fusion proteins, nitro blue tetrazolium/5-bromo-4-chloro-
-indoyl phosphate (NBT/BCIP) was used as AP substrate. For
uantification of bound proteins, p-nitrophenyl phosphate was em-
loyed as the substrate for measurement at an absorbance of 405
m. Apparent kD was calculated with Graphpad Prism software by
onlinear regression using a one-site binding model. Results were
btained from three independent experiments.
n Situ Hybridization
ouse cDNA sequences for TROY (bp 88–504), CD40 (bp 76–579),
R6 (bp 124–1053), p75 (bp 795–1254), LINGO-1 (bp 1–1000), and
gR (bp 97–923) were subcloned into pBluescript II SK+ (Strata-
ene). In vitro transcription was performed from linearized plasmids
sing T7 and T3 RNA polymerase (Promega) with digoxigenin-UTP
Roche) for synthesis of sense and antisense probes, respectively.
rozen sections of brain, DRGs, and retina were prepared from
-week-old adult C57BL/6 mice. In situ hybridization was per-
ormed as described previously (He and Tessier-Lavigne, 1997). Af-
er hybridization, mRNA localization was detected with AP-conju-
ated anti-digoxigenin Fab fragments followed by visualization
ith NBT/BCIP.
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ine at http://www.neuron.org/cgi/content/full/45/3/345/DC1/.
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